fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Donepezil HCL

All products: not a benefit

Sandoz Donepezil ODT · DIN 02367688 · 5 mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2020-08-10 — choose a marketed DIN from the same-category list.Discontinued August 10, 2020 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2020-08-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-08-10 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Sandoz Donepezil ODT · DIN 02367688 Manufacturer: Sandoz Canada Inc.; listing date 2014-05-29 Health Canada: Cancelled post market since 2020-08-10 · brand SANDOZ DONEPEZIL ODT · ATC N06DA02 DONEPEZIL · form Tablet (orally-disintegrating) · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 5 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02367688)

Source record
DIN 02367688: Sandoz Donepezil ODT Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 120400033; group id 192; item number 0352; lccId None; manufacturer id SDZ Source form: Orally Disintegrating Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $3.6176; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02367688 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85254
Interchangeable products
Aricept RDT · DIN 02269457 · not recorded Co Donepezil ODT · DIN 02397617 · not recorded
Shortage status: resolved shortage (ended August 10, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02367688
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 10, 2020 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (N06DA): coverage varies; not interchangeable

  • Galantamine (Reminyl ER): limited Use 347, 348, not a benefit
  • Rivastigmine (Exelon): limited Use 347, 348, not a benefit
Other drugs in the same formulary class (12:04 Parasympathomimetic (Cholinergic) Agents) and how they are covered

Matched class: 12:04 Parasympathomimetic (Cholinergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETHANECHOL CHLORIDE, CARBACHOL, PYRIDOSTIGMINE BROMIDE 12:04 Parasympathomimetic (Cholinergic) Agents

GALANTAMINE HYDROBROMIDE

· 18 products · Listed, not a benefit (3), Limited Use, codes 347, 348 (15) · strengths: 8mg, 16mg, 24mg · ER Cap

RIVASTIGMINE

· 34 products · Limited Use, codes 347, 348 (28), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.5mg, 3mg, 4.5mg, 6mg, 9mg/5 Sq Cm, 18mg/10 Sq Cm · Cap, Trans Patch

BETHANECHOL CHLORIDE

· 3 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CARBACHOL

· 1 products · General benefit · strengths: 2mg · Tab

PYRIDOSTIGMINE BROMIDE

· 4 products · General benefit · strengths: 180mg, 60mg · LA Tab, Tab

PILOCARPINE HCL

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:04
Full class listing Related classes: 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: dementia of the alzheimers type
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. GALANTAMINE HYDROBROMIDE · Listed, not a benefit (3), Limited Use, codes 347, 348 (15) Indications Galantamine ER (galantamine extended release capsules) is indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer’s type. PM: https://pdf.hres.ca/dpd_pm/00085752.PDF; date 2026-08-11; DIN 02316943; fetched 2026-09-10 Product monograph RIVASTIGMINE · Limited Use, codes 347, 348 (28), Off-Formulary Interchangeable, not an ODB benefit (6) 1 INDICATIONS EXELON® (rivastigmine hydrogen tartrate) is indicated for: • The symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type. PM: https://pdf.hres.ca/dpd_pm/00085220.PDF; date 2026-07-02; DIN 02242115; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS ARICEPT (donepezil hydrochloride) is indicated for: • symptomatic treatment of patients with mild, moderate and severe dementia of the Alzheimer’s type. Efficacy of ARICEPT in patients with mild to moderate Alzheimer’s disease was established in two 24 week and one 54-week placebo-controlled trials. Efficacy in patients with severe Alzheimer’s disease was established in three 24-week/6-month placebo-controlled trials. ARICEPT tablets should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of Alzheimer’s disease. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Dose escalation in patients > 85 years old should proceed with caution (see 4.1 Dosing Considerations; and 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00077966.PDF PM date: AUG 12, 1997 Source product: ARICEPT; DIN 02232043; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Sandoz Donepezil ODT: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026